Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H19N3O6
CAS Number:
Molecular Weight:
265.26
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:
Product Name
L-Ornithine L-aspartate salt, powder
form
powder
InChI key
IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
InChI
1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
SMILES string
NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O
assay
≥98% (TLC)
color
white to off-white
storage temp.
2-8°C
Quality Level
Looking for similar products? Visit Product Comparison Guide
Related Categories
Biochem/physiol Actions
L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.
Other Notes
Product of arginine degradation by arginase
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
José Luis Pérez Hernández et al.
Annals of hepatology, 10 Suppl 2, S66-S69 (2012-01-18)
Introduction. Hepatic encephalopathy (HE) refers to a complex neuropsychiatric syndrome that is progressive but potentially reversible and may have a significant impact on quality of life, as it is characterized by alterations in cognitive function, behavior and personality as well
Imre Fehérvári et al.
Magyar sebeszet, 65(2), 58-62 (2012-04-20)
About 6500-7000 people/year die in Hungary due to liver cirrhosis which is often complicated with hepatic encephalopathy (HE). While conventional interpretation is that hepatic encephalopathy is a consequence of high blood ammonia level, recent data indicate that the degree of
Shahab Abid et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 21(11), 666-671 (2011-11-15)
To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy (HE). Randomized placebo controlled study. The Aga Khan University Hospital, Karachi in the year 2003-2004. Patients with HE were randomized to receive LOLA
Irfan Ahmad et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 18(11), 684-687 (2008-11-06)
To determine the efficacy of L-ornithine-L-aspartate in treatment of hepatic encephalopathy. Randomized, placebo-controlled trial. Department of Gastroenterology and Hepatology, Sheikh Zayed Hospital, Lahore, from February to August 2005. Cirrhotic patients with hyperammonemia and overt hepatic encephalopathy were enrolled. Eighty patients
[New approach to diagnostics and correction of portohepatic hemodynamics in patients with chronic liver diseases].
S Iu Ermolov et al.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, (4)(4), 82-87 (2008-04-16)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service